UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000027338 |
|---|---|
| Receipt number | R000031085 |
| Scientific Title | A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer(TORG1632). |
| Date of disclosure of the study information | 2017/05/15 |
| Last modified on | 2022/09/01 15:49:37 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/05/14 20:50:29 | ||
| 2 | Update | 2018/09/18 10:24:05 | Recruitment status Last follow-up date |
|
| 3 | Update | 2019/11/15 09:23:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Organization Address Address Tel |
|
| 4 | Update | 2019/11/15 09:25:51 | Number of participants that the trial has enrolled |
|
| 5 | Update | 2019/11/15 09:32:33 | Date of IRB |
|
| 6 | Update | 2020/05/16 14:06:25 | Date of closure to data entry Date trial data considered complete |
|
| 7 | Update | 2020/11/15 17:28:30 | Recruitment status |
|
| 8 | Update | 2020/11/26 10:00:14 | Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 9 | Update | 2020/11/26 10:12:04 | Recruitment status |
|
| 10 | Update | 2022/08/30 16:11:22 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 11 | Update | 2022/08/31 16:00:16 | Results Results |
|
| 12 | Update | 2022/08/31 16:11:06 | Name of person sending information Name of person sending information |
|
| 13 | Update | 2022/09/01 15:49:37 | Results Results Adverse events Adverse events |
